Cost-effectiveness of FDG-PET

This study has been completed.
Netherlands: Ministry of Health, Welfare and Sports
Information provided by (Responsible Party):
Juliano Julio Cerci, University of Sao Paulo Identifier:
First received: September 20, 2011
Last updated: NA
Last verified: September 2011
History: No changes posted

Evaluation of cost-effectiveness of FDG-PET for the public health system in Brazil.

Oncologic Patients

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Estudo de Custo-efetividade Para o Sistema único de Saúde - SUS Sobre o Exame de Metabolismo de Glicose Marcada Com Flúor-18 Pela Tomografia de emissão de pósitron-PET

Further study details as provided by University of Sao Paulo:

Enrollment: 500
Study Start Date: June 2005
Study Completion Date: September 2011
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
oncologic patients
initial staging

Detailed Description:

To provide detailed information about cost and effectiveness of FDG-PET in multiple oncological diseases, such as Lymphoma, lung cancer and esophageal cancer.


Ages Eligible for Study:   13 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

500 oncologic patients


Inclusion Criteria:

  • Cancer

Exclusion Criteria:

  • Other malignancy
  • Uncontrolled Diabetes
  • Pregnancy
  Contacts and Locations
No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Juliano Julio Cerci, Pesquisador executante, University of Sao Paulo Identifier: NCT01438164     History of Changes
Other Study ID Numbers: USP0460/05
Study First Received: September 20, 2011
Last Updated: September 20, 2011
Health Authority: Brazil: Ethics Committee

Keywords provided by University of Sao Paulo:
Evaluate the cost impact in the evaluation of oncologic patients. processed this record on April 15, 2014